Introduction
Wilms' tumour (WT) or nephroblastoma is the most frequent kidney cancer in children. It affects 1 in 10 000 children, usually around the age of 5 years. Most cases are sporadic and unilateral, with bilateral tumours accounting for 7% of cases. A family history of WT is observed in 2% of cases. This tumour may also arise in association with rare malformation syndromes: WAGR syndrome (WT, aniridia, genitourinary malformations and mental retardation), Denys -Drash syndrome (DDS) and Beckwith -Wiedemann syndrome (BWS).
The WT1 gene, located at 11p13, encodes a zinc finger transcription factor involved in renal and gonad development (Hastie, 2001; Mrowka and Schedl, 2000) . Two alternative splicing sites give rise to four major isoforms. The alternative splicing of exon 5 results in the inclusion or omission of 17 amino acids in the transcriptional regulation domain of the protein. The second alternatively spliced region corresponds to three amino acids (KTS) located between the third and fourth zinc fingers of the DNA-binding domain. The four isoforms are produced in a constant ratio that is conserved between species, suggesting that they have non-overlapping functions. WT1 (-KTS) proteins regulate in vitro the transcription of genes essential for kidney development, such as IGF2, PDGFA, EGFR, PAX-2, and WT1 itself (reviewed in Menke et al., 1998) . Other potential targets, such as amphiregulin and RbAP46, have been identified by expression profiling (Guan et al., 1998; Lee et al., 1999) . It is now clearly established in vivo that the function of WT1 as a transcription regulator is modulated by post-transcriptional modifications and by interaction with other proteins including SF1, p53, PAR4 and CBP (Nachtigal et al., 1998; Maheswaran et al., 1993; Richard et al., 2001; Wang et al., 2001) . Exon 5 encodes an additional regulator domain, with potential repressor and activator functions (Reddy et al., 1995; . WT1 (+KTS) proteins have a low affinity for DNA and may be involved in RNA splicing (Larsson et al., 1995; Davies et al., 1998) . The presence of both the WT1 (+KTS) and WT1 (-KTS) isoforms is essential for normal urogenital development (Barbaux et al., 1997; Hammes et al., 2001) . Furthermore, the balance between WT1 (+exon 5) and WT1 (-exon 5) appears to be essential for the regulation of major cellular functions such as proliferation, differentiation and apoptosis (Englert et al., 1997; Hewitt and Saunders, 1996; Kudoh et al., 1995; Mayo et al., 1999) .
In Wilms' tumours in patients with WAGR and Denys -Drash syndromes, a first germline event at the WT1 locus (deletion or mutation) accounts for predisposition and is usually followed by a somatic mutation or loss of the normal allele (Jeanpierre et al., 1998) . In sporadic tumours, somatic mutations in WT1 are rare. However, we recently described changes in WT1 transcription in 90% of cases (Baudry et al., 2000) . A disruption of exon 5 splicing, with a relative decrease in the amount of the WT1 (+exon 5) isoforms, was the most frequent alteration, observed in 56% of the tumours. It was thought probable that these changes would affect the regulation of genes downstream in the WT1 pathway. Moreover, little is currently known about the genes and mechanisms that control WT1 expression and alternative splicing.
We recently reported preliminary data on expression profiling in Wilms' tumours using cDNA macroarrays, resulting in the identification of 153 genes differentially expressed in tumours and normal kidneys (Rigolet et al., 2001) . We now describe a more specific cDNA macroarray approach, intended to identify genes likely to be dysregulated in tumours with a decreased WT1 exon 5 +/7 isoform ratio. This approach was based on cDNA profiling of pools of tumours classified according to whether isoform imbalance was present or not. First, we identified 14 genes that displayed specific dysregulation in the pool of tumours with imbalance. Second, we validated the pooling strategy for tumour profiling, by RT -PCR analysis of four genes. Third, we extended the analysis of one of the down-regulated genes, VEGF, to 51 tumours by real-time RT -PCR, and showed that the level of expression of this gene correlated with the pattern of WT1 expression. Fourth, we analysed the prognosis significance of VEGF expression level.
Results

RNA profiling of pools of tumours with decreased and normal WT1 exon 5 +/7 isoform ratios
We probed Atlas Human Cancer cDNA expression arrays (Clontech), containing 588 genes involved in various aspects of malignancy and belonging to different functional classes, with cDNAs from: (1) tumours with a decreased exon 5 +/7 ratio and a normal KTS +/7 ratio, either as a pool (WT(UNB1)) or individually (WT9, WT53); (2) a pool of tumours with exon 5 +/7 and KTS +/7 ratios similar to those in normal kidneys (WT(NK-like)); (3) a pool of normal kidneys (NK) and (4) a pool of foetal kidneys (FK). Comparison of the expression profiles of WT(UNB1) and WT(NK-like) pools of tumours revealed 81 differentially expressed genes. We then considered the expression pattern of normal kidneys (NK), foetal kidneys (FK) and independently analysed tumours WT9 and WT53. Tumours WT9 and WT53 had the same WT1 isoform profile as tumours included in the WT(UNB1) pool. We selected those of the 81 genes which presented levels of expression: (1) similar in WT(UNB1), WT9 and WT53; (2) similar in WT(NK-like) and NK; (3) different in WT(UNB1) and NK; (4) different in WT(UNB1) and FK. Fourteen genes met these criteria, among which six were downregulated and eight were up-regulated in WT(UNB1) (Figure 1 ).
Validation of cDNA pooling for identification of differentially expressed genes
We analysed two overexpressed genes (CCND2 and PCNA) and two underexpressed genes (IGFBP5 and VEGF), by semi-quantitative RT -PCR using pooled cDNAs and individual cDNAs (WT9, WT77, WT84, WT97, WT190, WT52, WT72, WT75, WT133, NK183, NK186, NK188 and NK189) at the same time ( Figure  2a) . Although different normalization parameters were used for the quantification of array hybridizations (global normalisation) and RT -PCR assays (HPRT as a control gene), differences in expression pattern between pool WT(UNB1) and pool WT(NK-like) were consistent for all four genes tested. Moreover, the levels of expression of the four genes in the individual tumours were consistent with levels of expression in the corresponding pools (Figure 2b ).
VEGF expression in a series of 51 tumours
We extended the analysis of VEGF expression to a series of 51 tumours, 13 normal kidneys and 2 foetal kidneys, using real-time RT -PCR. Normal and foetal kidney VEGF expression levels were evaluated as 0.99+0.49 and 0.82+0.05 respectively, according to R ratios (see Materials and methods). Thirty-seven tumours underexpressed VEGF (R50.5) and six tumours overexpressed VEGF (R41.5) ( Table 1) . Decreased expression in tumours was confirmed by comparing the level of expression in seven tumours and paired normal kidneys (Figure 3 ). The WT1 expression of the tumours was assessed in a previous study (Baudry et al., 2000) . We compared the expression of VEGF and WT1 and found that 29 out of 34 tumours (85%) with a decreased WT1 exon 5 +/7 ratio or no WT1 expression (no transcript or truncated protein) underexpressed VEGF. There was no difference in VEGF expression between tumours with an abnormal KTS +/7 ratio and tumours with a normal KTS +/7 ratio. Furthermore, all three tumours with an increased WT1 exon 5 +/7 ratio (UNB2) expressed VEGF at a higher level. There was no evidence of a correlation between the level of VEGF expression and treatment or not by preoperative chemotherapy (Table 1) .
Finally, we investigated the correlation between VEGF expression in tumours and prognosis. We compared two categories of patients with relapse, those who are alive (six patients) and those who died (five patients). Patients with rhabdoid tumours were excluded from this analysis. Although none of the 11 tumours overexpressed VEGF, VEGF levels were significantly higher in the tumours from patients who 
Discussion
The heterogeneity of Wilms' tumours is reflected in the large number of genes with differential expression in tumours and normal kidneys (Rigolet et al., 2001) . The approach described here, based on tumour pooling for profiling, made it possible to reduce this heterogeneity artificially and to select 14 genes more specifically dysregulated in a pool of tumours with decreased exon 5 +/7 ratio. Seven of these genes had not been identified by our previous study. We validated the pooling strategy for cDNA profiling, by comparing the levels of expression of four of the 14 genes (PCNA, CCND2, IGFBP5 and VEGF) in individual and pooled samples by RT -PCR.
Dysregulation of the 14 genes was associated with decreased WT1 exon 5 +/7 ratio. However, we cannot rule out an effect due to changes in the overall level of expression of WT1, because most tumours with exon 5 +/7 imbalance also had higher overall levels of expression than did tumours with a normal exon 5 +/7 ratio. Moreover, somatic mutations were investigated only in tumours associated with a predisposing syndrome. In sporadic tumours, WT1 mutations are rare. However, we cannot exclude that unidentified somatic mutations could alter the WT1 function in a few cases.
At present, we have no evidence that alterations of WT1 expression are causally related to changes in gene expression of the 14 differentially expressed genes, and several hypotheses can be put forward. The first hypothesis is a direct transcriptional regulation by WT1. We identified consensus sequences for WT1 binding in the promoters of N-MYC, CCND2, VEGF, C-FOS and IGFBP5. Direct regulation of the expression of N-MYC by WT1 have already been reported (Zhang et al., 1999) . Reporter gene assays are now required to investigate whether the other genes are genuine transcriptional targets of WT1 or not. As a second hypothesis, indirect transcriptional regulation by WT1, or WT1 exon 5 +/7 isoform imbalance as a downstream event, must be considered. As a third hypothesis, WT1 isoform imbalance and dysregulation of expression of the 14 genes may be correlated in tumours, but not causally linked. Analysis of the expression of these genes in a larger series of tumours is required to evaluate by accurate statistical analysis UNB2=increased exon 5+/7 ratio; NK-like and FK-like=exon 5+/7 ratio as in normal and foetal kidneys respectively; *increased KTS+/7 ratio; the overall level of WT1 expression in tumour is shown in comparison with that in normal kidneys. Stage, histological and follow up data are from SIOP studies (SIOP 6, 9 and 93). #tumours used for hybridization on macroarrays
Expression profiling of Wilms' tumours D Baudry et al the validity of a classification based on expression profiles. The WT1 exon 5 +/7 ratio has been reported to be involved in the control of proliferation and differentiation (Hewitt and Saunders, 1996; Kudoh et al., 1995) . Four of the eight overexpressed genes, CCND2, E2F3, PCNA, and N-MYC, are involved in cell cycle control and proliferation. CCND2, encoding the regulator subunit of cyclin D2/cyclin dependent kinase complexes, and the transcription factor E2F3 are critical for control of the G1/S transition (Sherr, 1996; Humbert et al., 2000) . PCNA plays an essential role in nucleic acid metabolism and is a sensitive indicator of cell proliferation (Kelman, 1997) . The transcription factor N-MYC is down-regulated when kidney differentiation occurs, and increases in the expression of N-MYC have already been reported in Wilms' tumours (Stanton and Parada, 1992; Nisen et al., 1986) . In vitro experiments previously demonstrated G1 phase arrest by WT1, with exon 5+ isoforms displaying greater efficiency than exon 57 isoforms (Kudoh et al., 1995) . The association between overexpression of these four genes and decreased WT1 exon 5 +/7 ratio suggest a specific mechanism in tumours with this imbalance.
In accordance with SIOP (International Society of Paediatric Oncology) protocols, most patients underwent preoperative chemotherapy treatment. The effect of such a treatment on expression levels in tumours has been reported for PCNA and TOP2A. A significant decrease in PCNA expression has been reported in Wilms' tumours after preoperative chemotherapy, the maintenance of a high level of expression being associated with a poor prognosis (Kim et al., 1996) . Topoisomerases are known targets of antitumour drugs and a decrease in TOP2A expression has also been reported in nephroblastomas after preoperative chemotherapy (Granzen et al., 2001) . In this report, three of the five tumours of pool WT(UNB1) with high levels of PCNA and TOP2A expression (WT9, WT84 and WT190) were not treated by preoperative chemotherapy. We therefore cannot exclude the possibility that the overexpression of these genes was Figure 2 Quantification by semi-quantitative RT -PCR of gene expression; (a) fragments specific to CCND2, PCNA and VEGF were co-amplified with a fragment specific to HPRT (hypoxanthine-guanine phosphoribosyl transferase) as a control. Pooled cDNAs were used, as previously described. For each cDNA pool, four 1 : 2 serial dilutions were amplified for 26 cycles to obtain reliable quantification in exponential conditions. (b) Comparison of the levels of expression of PCNA, CCND2, IGFBP5 and VEGF, with that of HPRT as a control, in pooled and individual cDNA samples. The results were normalized with respect to the mean level of expression in normal kidneys due to the lack of preoperative chemotherapy rather than to changes in WT1 expression. TIMP3 and IGFBP5 belong to gene families whose members have already been implicated in Wilms' tumours. Tissue inhibitors of metalloproteases (TIMPs) play a key role in extracellular matrix metabolism and are involved in tumour progression (DeClerck et al., 1992) . A lack of expression of TIMP4 has been reported in Wilms' tumours (Celiker et al., 2001 ). In our experiments, the level of TIMP4 expression in tumours and normal tissues was too faint to allow quantification, but we report a decrease in TIMP3 expression. TIMP3 has also been incriminated in various tumours (Bachman et al., 1999) . IGFBPs are important regulators of IGF1 and IGF2 function (Rechler and Clemmons, 1998) . IGFBP3 and IGFBP4 have been reported to be underexpressed in cells displaying truncation of WT1 (Wagner et al., 2001 ). Here we report a down-regulation of IGFBP5, a gene associated with mesenchyme -epithelial transition during kidney development (Plisov et al., 2000) . As IGF2 is frequently overexpressed in Wilms' tumours, the down-regulation of IGFBPs may be a mechanism by which an excess of functional IGF2 could be generated.
Analysis of the expression of VEGF in 51 tumours showed underexpression, not only in tumours with a decreased exon 5 +/7 ratio, but also in tumours devoid of normal WT1 protein. Conversely, the highest levels of expression were observed in the few tumours with a high exon 5 +/7 ratio. This suggests that two subtypes of WT may be defined according to WT1 and VEGF expression. The observation of VEGF underexpression in most tumours contrasts with the frequent observation of VEGF overexpression in various tumours, which is correlated with a poor prognosis (Linderholm et al., 2001; Yuan et al., 2001) . Overexpression of VEGF was observed in only six tumours and all these patients are alive without relapse, with a follow-up of at least 6 years. However, among patients with relapse, we observed that the level of VEGF expression, studied in initial tumours, was significantly higher if fatal outcome occurred than if patients recovered. It suggests that the level of VEGF expression, albeit low, may have a prognosis value for Wilms' tumours. This is in agreement with data showing that VEGF production is associated with tumour growth and metastases in a murine model of Wilms' tumour (Kayton et al., 1999; Rowe et al., 2000) . Analysis of a larger number of tumours is now necessary in order to validate the use of VEGF as a prognosis marker.
cDNA arrays have proven to be powerful tools not only for tumour classification but also for identification of regulation pathways. Our analysis of differential expression profiles in tumour pools allowed us to identify 14 genes dysregulated in association with a decreased WT1 exon 5 +/7 isoform ratio. These data provide a starting point for investigations of the way in which these genes may be involved in the nephroblastoma tumorigenic process, and their relationship with WT1 pathways. They also provide preliminary data towards a classification based on expression profiles. Such a classification will be helpful not only to determine how many Wilms' tumour subtypes exist, but also to determine whether there is any particular relationship between the changes in gene expression and pathological features.
Materials and methods
Samples
Tumours were collected from 50 patients. All these patients were included in International Society of Paediatric Oncology (SIOP) treatment protocols. Clinical and histological data are summarised in Table 1 . WT1 analysis for these tumours has been reported elsewhere (Baudry et al., 2000) . The WT(UNB1) pool included five tumours with lower than normal exon 5 +/ 7 isoform ratios and a normal KTS +/7 isoform ratio: WT9, WT77, WT84, WT97 and WT190. The WT(NK-like) pool included four tumours with exon 5 +/7 and KTS +/7 isoform ratios similar to those in normal kidney: WT52, WT72, WT75 and WT133. The NK pool included five normal kidneys: NK182, NK183, NK186, NK188 and NK189. Foetal kidney (FK) samples were obtained from 23-week-old (FK1) and 20-week-old (FK3) foetuses. FK (five samples, 19 -23 weeks) polyadenylated RNA was purchased from Clontech and used as the FK pool.
Total RNA extraction and cDNA preparation Total RNA was prepared from frozen tissues using Trizol reagent, according to the manufacturer's protocol (Life Technologies). We reverse transcribed 5 mg of each RNA with 200 U of SuperScriptII reverse transcriptase and hexanucleotide random primers according to the manufacturer's recommendations (Life Technologies). The resulting cDNA solution was diluted to a final volume of 100 ml, 2 ml of which was used for PCR amplification.
cDNA macroarray hybridisation and data acquisition Gene expression was analysed using Atlas Human Cancer cDNA expression arrays (Clontech). For expression profiling of tumour pools, equal amounts of total RNA from the tumour samples to be pooled were mixed and cDNA was synthesized from 5 mg of each mix, as previously described (Rigolet et al., 2001) . Following hybridisation, membranes were placed against a Phosphor Screen for 2 days to 1 week and scanned with a PhosphorImager (Molecular Dynamics). Data were saved as 'gel format' files and analysed using the AtlasImage 1.5 software (Clontech). The hybridization of individual tumour samples and normal controls has already been reported (Rigolet et al., 2001) and 'gel format' files were used for analysis with the AtlasImage 1.5 software. We considered a spot signal to be meaningful if its adjusted intensity (spot signal intensity minus background signal intensity) was at least equal to background signal intensity. As each cDNA sample was hybridized in triplicate, we performed a 'composite' analysis: the software calculated the mean of the three results for each spot position. Global normalization with the Sum method was used to compare composites two by two. A gene was regarded as differentially expressed if the adjusted intensity of the signal for one of the composites was higher or lower, by a factor of at least two, than that of the other.
RT -PCR analysis of candidate genes
For each sample, four 1 : 2 serial dilutions of the cDNA were amplified for 26 cycles, using candidate gene and HPRT primers (Table 2) . 32 P-dCTP was added to the reaction mixture for radiolabelling of the PCR products. We determined the ratios of candidate gene to HPRT by phosphorimaging and analysis with ImageQuant software (Molecular Dynamics). For each data point, the results of two or three successive cDNA dilutions in the non-saturated range of PCR were averaged. Two independent experiments were performed.
Quantification of VEGF expression by real-time RT -PCR
Real-time RT -PCR was performed with an ABI Prism 7700 (PE Biosystems) according to the manufacturer's instructions. We independently amplified VEGF and three control genes, HPRT, S9 and ACTB. Reactions were performed in a 20 ml volume with 10 pmoles of each primer. Deoxyribonucleotides, Taq DNA polymerase and buffer were included in the SYBR Green PCR Master Mix (PE Biosystems). We quantified the amount of amplified fragments with Sequence Detector v1.6 software. For each sample, three ratios were calculated: R HPRT =VEGF/HPRT, R S9 =VEGF/S9 and R ACTB =VEGF/ACTB. Ratios for the 13 normal kidneys were averaged to give R(NK) HPRT, R(NK) S9 and R(NK) ACTB . For each tumour and normal kidney sample, R ratios were then normalized with respect to the appropriate R(NK) ratio: R(norm) HPRT =R HPRT / R(NK) HPRT ; R(norm) S9 =R S9 /R(NK) S9 ; R(norm) ACT-B =R ACTB /R(NK) ACTB . Finally, we calculated an R ratio as the mean of these three R(norm) ratios. We considered the level of VEGF expression to be lower or higher in a tumour sample than in normal kidneys if R was lower or higher than the mean normal kidney R ratio minus or plus one standard deviation. For analysis, we considered the mean of the results obtained in two independent experiments. 
